11:43 AM EST - Valeant Pharmaceuticals International, Inc. : announced that it has entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Obagi Medical Products, Inc. for $19.75 per share in cash, which represents a 28% premium to Obagi's closing share price on March 19, , the last trading day prior to announcement. Valeant Pharmaceuticals International, Inc.
shares T.VRX are trading up $2.33 at $75.68.
